A Medical Device Daily
St. Jude Medical (St. Paul, Minnesota) reported FDA and CE-mark approvals of EonC, the first extended-life primary cell (non-rechargeable) neurostimulator for the treatment of chronic pain.
The EonC neurostimulator provides an option for chronic pain patients who prefer or require a non-rechargeable medical device.
"Selecting the right system for each patient is vital for the success of spinal cord stimulation (SCS) therapy," said Chris Chavez, president of St. Jude's Advanced Neuromodulation Systems (ANS) division. "With chronic pain, there's no such thing as a 'one size fits all' approach. For some patients, a non-rechargeable device like EonC provides the perfect solution for their needs."
Neurostimulators like EonC are designed to provide SCS therapy to treat complex neuropathic pain of the trunk and limbs or pain from failed back surgeries. Similar in function and appearance to cardiac pacemakers, these devices deliver mild electrical pulses to the spinal cord, interrupting or masking the pain signals' transmission to the brain.
More than 35,000 patients in 35 countries have been implanted with neurostimulation systems from St. Jude.
The company says that the EonC is the only 16-contact, constant current, non-rechargeable system for SCS therapy.
The ANS division of St. Jude Medical makes implantable neuromodulation systems to improve the quality of life for people suffering from disabling chronic pain and other nervous system disorders.